Gert De Meerleer is currently head-of-clinics at the department of Radiation Oncology at University Hospital Leuven.\u00a0 His main field of interest is urologic oncology with a focus on implementing modern radiation technology in the treatment of prostate cancer, kidney cancer, testicular cancer and to a lesser extent, bladder cancer.\u00a0 <\/p>\n
He has pioneered the implementation of stereotactic body radiotherapy in the treatment of oligometastatic prostate cancer, which has led to a paradigm shift in the treatment of these patients.
\n\u00a0
\nGert De Meerleer successfully defended his PhD in 2000.\u00a0 In this PhD, he described the implementation of intensity-modulated radiotherapy in the treatment of prostate cancer.\u00a0 Since then, he (co-)promoted several other PhD\u2019s, most of them dealing with the implementation of intensity-modulated radiotherapy (including arc therapy) in the treatment of urological and, to a lesser extent, gynaecologic malignancies. \u00a0
\n\u00a0
\nHe is an active member of the multidisciplinary working group of urological malignancies at Leuven University Hospital.\u00a0 He has also (co-)authored more than\u00a0150 A1 publications,\u00a0most of them in the field of urological oncology, co-edited several booklets on prostate cancer and was granted several times and by different organizations (FWO, VLK, Stichting tegen Kanker, Movember) for his scientific research.
\n\u00a0
\nHe is full professor at Leuven (KUL), with a main focus on scientific research in the treatment of urologic malignancies, with a special focus on the interaction of stereotactic body radiotherapy and systemic treatments.\u00a0 He pioneered the implementation of metastasis-directed therapy in the treatment of oligometastatic urologic malignancies.
\n\u00a0
\nGert De Meerleer is co-president of the Belgian Radiotherapy Awareness and Visibility Organization (BRAVO), \u00a0board member of Scientific Summits, a high-level scientific Belgian organization and a member of the scientific jury of the \u201cFederation against Cancer\u201d.\u00a0
\n\u00a0
\nHe is an experienced international speaker at urologic and oncologic congresses, a reviewer for several international cancer organizations and high-ranked journals and is also involved in teaching within Belgium and Europe.<\/p>\n","protected":false},"author":{"id":1,"first_name":"Francisco","nickname":"Superadmin","email":"jose.santos@cor2ed.com"},"featured_media":188,"menu_order":99,"template":"","groups":[],"class_list":["post-189","experts","type-experts","status-publish","has-post-thumbnail","hentry"],"expert_info_prefix":"Prof.","expert_info_first-name":"Gert","expert_info_last-name":"De Meerleer","expert_info_institution":"University Hospital Leuven","expert_info_country":"BE","expert_info_specialization":"Radiation Oncologist","expert_info_map-code":"","expert_info_disclosures":"","expert_info_linkedin":"","expert_info_twitter":"","expert_info_instagram":"","expert_info_facebook":"","_links":{"self":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts"}],"about":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/types\/experts"}],"version-history":[{"count":0,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/media\/188"}],"wp:attachment":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/media?parent=189"}],"wp:term":[{"taxonomy":"groups","embeddable":true,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/groups?post=189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}